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ABSTRACT
The utility of diagnostic studies to determine the aetiology of community-acquired pneumonia is
controversial because of the lack of rapid, easily performed, accurate, cost-effective methods that
provide immediate results for the majority of patients at the initial evaluation by a clinician in an ofﬁce
or acute-care setting. Nevertheless, there are good reasons for establishing an aetiological diagnosis,
namely to direct antibiotic management for an individual patient, to facilitate management of treatment
failure and, by de-escalation or narrowing of antibiotic therapy, to potentially decrease healthcare costs,
drug side-effects and the selection pressure for antibiotic resistance. This article outlines the clinical
value of Gram’s stain and brieﬂy surveys current tests for Streptococcus pneumoniae based on
immunological and molecular assays.
Keywords Pneumococcus, pneumonia, rapid detection
Clin Microbiol Infect 2006; 12 (suppl 9): 27–33
INTRODUCTION
Although numerous pathogens can cause com-
munity-acquired pneumonia (CAP), Streptococcus
pneumoniae remains the leading bacterial cause
and the leading cause of mortality [1]. It is
essential that initial empirical therapy of CAP
be effective against this important pathogen.
However, the empirical therapy of CAP has
become more complicated over the past several
decades, owing to the emergence of newly
recognised pathogens (i.e., several ‘atypical’
pathogens and viruses) as well as the increasing
emergence of pneumococcal strains resistant to
penicillin and other antimicrobial agents. While
the clinical relevance of much of the in-vitro
resistance in S. pneumoniae is questionable, the
presence of high-level resistance (e.g., a penicil-
lin MIC >4 mg ⁄L) does seem to affect treatment
outcomes [2]. In addition, resistant pneumococ-
cal infection in patients who require hospitali-
sation is associated with increased length of stay
and cost of care [2].
In light of these concerns regarding the empir-
ical therapy of CAP, it is important to examine the
potential impact of the rapid diagnosis of S. pneu-
moniae as the cause of an infection in a speciﬁc
patient. This article reviews the available tests that
allow the rapid detection of S. pneumoniae—
namely Gram’s stain and immunological and
molecular assays—and discusses their clinical
usefulness in directing antimicrobial therapy.
GRAM’S STAIN
The value of routinely performing a Gram stain of
the sputum and culture has long been debated.
These tests are limited by the fact that many
patients cannot produce a good specimen,
patients often receive antimicrobial agents prior
to evaluation, and many specimens give incon-
clusive results.
The validity of Gram’s stain is related directly
to the experience of the interpreter. Indeed, some
discrepant ﬁndings concerning the Gram stain of
the sputum are presumably explained by the
quality of specimens and the technical expertise
of medical staff. When stringent criteria are
applied, although the sensitivity drops, the
speciﬁcity for pneumococcal pneumonia can
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approach 90%. For example, the yield of S. pneu-
moniae is only 40–50% from sputum cultures
obtained from patients with bacteraemic pneu-
mococcal pneumonia in studies done a few
decades ago [3,4]. A more recent study of 100
bacteraemic pneumococcal pneumonias found
that sputum specimens were not submitted in
31% of cases and were judged as inadequate in
another 16% of cases [5]. If patients receiving
antibiotics for >24 h were excluded, Gram’s stain
showed S. pneumoniae in 63% of cases and the
culture was positive in 86%. For patients who had
not received antibiotics, Gram’s stain was read as
being consistent with S. pneumoniae in 80% of
cases and sputum culture was positive in 93%.
While favourable reports of Gram’s stain have
been published, a meta-analysis showed a low
yield in terms of the number of patients with
adequate specimens and deﬁnitive results [6]. At
least 40% of patients are unable to produce any
sputum or sputum in a timely manner, and while
the yield of cultures is substantially higher with
endotracheal aspirates, bronchoscopic samples
or trans-thoracic needle aspirates, specimens
obtained after initiation of antibiotic therapy are
unreliable and must be interpreted carefully. A
ﬁnal limitation of the sputum Gram’s stain,
especially as applied in the USA, is the notable
decline in its use by house staff and attending
physicians when initially evaluating patients with
pneumonia. This is in part due to the Clinical
Laboratory Improvement Act of 1988, which
required that staff have credentials to interpret
Gram’s stains of any specimens. In addition,
outsourcing of specimens to laboratories outside
the hospital leads to delays in processing and less
direct communication between the microbiology
laboratory and the clinician.
IMMUNOLOGICAL ASSAYS
Immunological assays are the most commonly
used rapid assays for S. pneumoniae. Tests that fall
into this category include counter-immunoelect-
rophoresis, co-agglutination, latex agglutination,
ELISA, immunoﬂuorescence and immunochro-
matography.
Counter-immunoelectrophoresis
Counter-immunoelectrophoresis is a relatively old
and labour-intensive technique. Its sensitivity in
diagnosing pneumococcal pneumonia by testing
serum, urine and bronchoalveolar lavage ﬂuid has
been shown to be low (not exceeding 50%) [7,8].
However, the technique is able to identify S. pneu-
moniae in blood cultures at least 24 h earlier than is
possible using subculturing, with almost 100%
sensitivity and speciﬁcity [9]. In the same manner,
agglutination tests have proved useful for the
rapid and speciﬁc identiﬁcation of pneumococcal
antigen blood culture bottles and for the preven-
tion of false-negative culture results caused by
autolysis of pneumococci during incubation.
Co-agglutination and latex agglutination
Pneumolysin-based co-agglutination and C-sub-
stance-speciﬁc latex agglutination are inexpen-
sive, easy to perform and to read, and are
relatively independent of antibiotic therapy.
These methods can be used for aetiological
diagnosis of pneumonia and meningitis by the
detection of pneumococcal antigens in sputum,
bronchoalveolar and pleural ﬂuid, serum, urine,
blood culture broth and cerebrospinal ﬂuid. They
are used mostly in laboratory settings, although
commercial kits are also available.
Serum co-agglutination tests show a sensitivity
of c. 90% in diagnosing pneumonia, while cere-
brospinal ﬂuid tests for meningitis show a sensi-
tivity of c. 71–97% [10,11]. The performance of
latex agglutination methods varies considerably,
depending upon the clinical specimen. Latex
agglutination had low sensitivity in detecting
pneumococcal antigen in serum (18–47%) and
urine (14–29%) [7], but was found to be very
sensitive when testing sputum (90–94%) and
blood cultures (100%) [12,13]. At the same time,
latex agglutination is characterised by high spe-
ciﬁcity. The technique is a frequently performed
laboratory procedure, but its clinical utility is
controversial. A review of 5169 assays (for
S. pneumoniae, group B streptococcus, Haemophilus
inﬂuenzae and Neisseria meningitidis) performed
over a 10-month period at two sites showed that
only 57 (1.1%) of tests were positive, of which 31
(54%) were false-positives [14]. Therapy was not
altered on the basis of any of the true-positive
results, but false-positive results led to additional
costs, prolonged hospitalisation and some clinical
complications. Thus, this retrospective study did
not support the use of latex agglutination for
rapid antigen detection.
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Elisa
ELISA-based rapid tests allow a diagnosis of
pneumococcal pneumonia to be made with a
sensitivity of >70% by the detection of capsular
antigen in serum [15] or pleural ﬂuid [16].
However, this method is not widely used and is
not yet commercially available.
Immunochromatography
Immunochromatography is a modern and fre-
quently used technique that can be used to
determine the aetiology of pneumonia, meningitis
and otitis media, to establish the diagnosis of
invasive pneumococcal disease, and for the docu-
mentation of nasopharyngeal colonisation with
S. pneumoniae. Several commercial kits based on
immunochromatography are currently available.
This technique is suitable for the identiﬁcation of
pneumococci in different types of clinical mater-
ial, as well as for the detection of antigenuria in
patients with pneumococcal diseases.
Urinary antigen tests are particularly attractive
for detecting pneumococcal pneumonia when
cultures cannot be obtained in a timely fashion
or when antibiotic therapy has already been
initiated. In serial specimens from known bacter-
aemic cases, the pneumococcal urinary antigen
detected by immunochromatographic assay was
still positive in 83% of cases after 3 days of
therapy [17]. This form of urinary antigen testing
has the principal additional advantages of rapid-
ity (c. 15 min), simplicity and reasonable specif-
icity in adults. Studies in adults have shown a
sensitivity of 50–80% and speciﬁcity exceeding
90% [18,19]. The immunochromatography assay
is also highly accurate in diagnosing pneumococ-
cal meningitis (95% sensitivity with cerebrospinal
ﬂuid, 57% sensitivity with urine, and 100%
speciﬁcity) [20].
The disadvantages of urinary antigen testing
include the cost and the lack of an isolated
organism for in-vitro susceptibility tests. Notably,
immunochromatography is not suitable for eval-
uation of therapeutic effect, because positive test
results are obtained for several weeks after recov-
ery. Moreover, the immunochromatographic
assays are non-speciﬁc for pneumococcal infec-
tions in children, particularly the very young,
since nasopharyngeal carriage of S. pneumoniae
can cause false-positive results [21]. Likewise, the
test may not be useful for predicting the aetiology
of disease in populations with a high rate of
pneumococcal nasopharyngeal carriage. False-
positive results have been seen in patients with
a prior episode of CAP within the previous
3 months, but they do not appear to be a signi-
ﬁcant problem in colonised patients with chronic
obstructive pulmonary disease [18].
Recent studies have evaluated the clinical utility
of urinary antigen testing for S. pneumoniae in
patients with CAP. Guchev et al. [22] prospec-
tively assigned patients with mild pneumonia to
two groups. Those with positive urinary antigen
test results were treated using pneumococcal-
directed therapy with amoxycillin. Those with
negative urinary antigen test results were treated
with clarithromycin, based on perceived likeli-
hood of infection by atypical pathogens. Of 219
evaluable patients, 22% had a positive urinary
antigen test result. There was no difference in the
outcomes of the two groups. Notably, 47 ⁄ 71 (62%)
of patients in whom an atypical pathogen was
identiﬁed were in the urinary antigen-negative
arm, while 24 (38%) were in the urinary antigen-
positive arm, indicating that they had S. pneumo-
niae in association with an atypical pathogen.
However, since the atypical pathogens were
determined by serological methods, these latter
cases might have represented a primary atypical
infection followed by secondary infection by
S. pneumoniae. In such cases, it is probable that
the clinical manifestations of infection that were
treated were attributable to S. pneumoniae, and this
may explain the good response to amoxycillin
alone.
The authors concluded that the urinary antigen
test allowed them to administer targeted therapy
with a penicillin-class antibiotic rather than a
broader-spectrum agent. Such narrow-spectrum
therapy can be more cost-effective and can allow
broad-spectrum agents, such as macrolides or
ﬂuoroquinolones, to be reserved for patients
whose urinary antigen test result is negative.
Potential cost reductions are likely to be inﬂu-
enced by price differences between the targeted
and broad-spectrum agents and by the proportion
of positive test results [23]. Also, it should be
noted that at the time of this study, in Russia,
there was little b-lactam or macrolide resistance in
S. pneumoniae. Thus, this approach may not be as
useful in areas where high-level penicillin resist-
ance exists. In addition, the study was performed
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in military trainees who were young (mean age,
19 years) and generally healthy. The authors
suggested that additional trials are necessary for
other clinical settings [22].
In another study, Stralin and Holmberg evalu-
ated the urinary antigen test in 215 hospitalised
patients with CAP, all of whom received initial
b-lactam monotherapy [24]. The median age was
74 years, and approximately 45% of patients had
a pneumonia severity index of class IV or V. Thus,
these patients were more severely ill than those in
the previously described study [22]. Thirty-eight
patients had a positive urinary antigen result for
S. pneumoniae, and 92% of these had a successful
outcome; 114 had a negative urinary antigen
result, and 78% of these had a successful out-
come. There were no patients with a positive PCR
sputum test result for an atypical pathogen in the
urinary antigen-positive group, whereas six pa-
tients had a positive PCR result for Mycoplasma
spp. or Chlamydophila spp. in the urinary antigen-
negative group. The authors suggested that a
positive urinary antigen test result supports treat-
ment with narrow-spectrum b-lactam antibiotics
and that additional coverage for atypical patho-
gens is needed more frequently in patients with
negative test results.
MOLECULAR ASSAYS
Molecular assays for S. pneumoniae include nu-
cleic acid ampliﬁcation techniques, i.e., PCR and
loop-mediated isothermal ampliﬁcation, and
DNA hybridisation.
PCR is a potentially attractive diagnostic tool
for rapid diagnosis, since it does not rely on
bacterial growth or the viability of the organism.
There is some evidence that PCR-based assays are
more sensitive than culture. PCR assays show
moderate sensitivity (43%) in tests of blood, and
high speciﬁcity in blood-culture-conﬁrmed pneu-
mococcal infections, and sometimes give positive
results in culture-negative samples [25]. PCR
techniques based on ampliﬁcation of the pneu-
molysin or autolysin genes are applicable for the
diagnosis of pneumonia, otitis media and menin-
gitis. In sputum tests, autolysin and pneumolysin
PCR has shown a high sensitivity (more than
80%), but a low speciﬁcity (30–40%) [26]. How-
ever, in pleural ﬂuid PCR detects the pneumoly-
sin gene with a sensitivity of 78% and a speciﬁcity
of 93% [27].
The interpretation of sputum PCR tests is
complicated by the difﬁculty in differentiating
between pneumococcal colonisation and true
infection. One approach that may help to resolve
this problem is the quantiﬁcation of the target
organism by real-time PCR. Yang et al. evaluated
the utility of a real-time pneumolysin gene PCR
test using sputum samples from patients admitted
with CAP [28]. Of 129 patients, 23% had S. pneu-
moniae isolated from blood or sputum. The sensi-
tivity and speciﬁcity using real-time PCR were
90% and 80%, respectively. Real-time PCR can
also detect S. pneumoniae in middle ear ﬂuid from
children with acute otitis media with a sensitivity
of 100% and a speciﬁcity of 73% compared to
culture [29].
Multiplex PCR allows the identiﬁcation of
several pathogens simultaneously in samples
from patients with pneumonia, meningitis and
otitis media with high levels of accuracy [30].
Loop-mediated isothermal ampliﬁcation is a
novel nucleic acid ampliﬁcation technique that
ampliﬁes DNA under isothermal conditions
(63C) with high speciﬁcity, efﬁciency and rapid-
ity. It is characterised by a sensitivity 1000 times
greater than that of conventional PCR [31].
PCR may therefore represent a useful diagnos-
tic adjunct to assist clinicians in the selection of
the most appropriate antibiotics. At present,
conventional culture methods will still be
required to conﬁrm the antimicrobial susceptibil-
ity of the organism. However, PCR techniques
also have the potential to be used for the rapid
detection of antimicrobial resistance in S. pneu-
moniae. Ampliﬁcation of the pneumococcal peni-
cillin-binding protein 2B gene can be used to
determine penicillin susceptibility, and provides
susceptibility data even in culture-negative cases.
The method has positive and negative predictive
values of 100% and 91%, respectively, and
showed 98.3% agreement with MIC data [32].
DISCUSSION
The utility of diagnostic studies to determine the
aetiology of CAP is controversial because of the
lack of rapid, easily performed, accurate, cost-
effective methods that provide immediate results
for the majority of patients at the point of service
(i.e., the initial evaluation by a clinician in an
ofﬁce or acute-care setting). Nevertheless, there is
a good rationale for establishing an aetiological
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diagnosis. The primary reason is to provide
results that inﬂuence the antibiotic management
of an individual patient. The selection of antibiotic
therapy can be broadened, narrowed or com-
pletely changed on the basis of accurate diagnos-
tic testing. Furthermore, management of early
antibiotic failure can be greatly facilitated by the
determination of an aetiological diagnosis.
De-escalation or narrowing of antibiotic therapy
on the basis of diagnostic testing may decrease
costs, drug side-effects and the selection pressure
for antibiotic resistance.
These considerations are important in light of
the speciﬁc impact of the rapid diagnosis of
S. pneumoniae. Since all recommended antimicro-
bial options for empirical therapy in most of the
published guidelines are effective against S. pneu-
moniae (including drug-resistant strains), it can be
argued that there is little need to identify S. pneu-
moniae in order to ensure appropriate therapy for
this pathogen. In addition, the possibility of
polymicrobial CAP and the potential beneﬁt of
combination therapy for bacteraemic pneumococ-
cal pneumonia have complicated the decision to
narrow antibiotic therapy, since the identiﬁcation
of S. pneumoniae may not preclude a second
pathogen. Furthermore, one randomised clinical
trial of a diagnostic strategy in CAP demonstrated
that, while there was a signiﬁcant increase in
diagnostic yield, there were no statistically signi-
ﬁcant differences in mortality or length of stay
between pathogen-directed therapy and empirical
therapy [33]. However, this study did not require
the alteration or speciﬁcation of therapy on the
basis of the results of the diagnostic tests. More-
over, the study was performed in a country with a
low incidence of antibiotic resistance (The Neth-
erlands), which may limit its applicability to areas
with higher levels of resistance. It is of interest
that pathogen-directed therapy was associated in
this study with a lower mortality rate in the small
number of patients admitted to the intensive care
unit. Adverse effects of treatment were signiﬁ-
cantly more frequent in the empirical therapy
group, but may be unique to the speciﬁc antibiotic
used (erythromycin). The absence of beneﬁt over-
all in this study should not be interpreted as an
absence of beneﬁt for an individual patient.
The identiﬁcation of S. pneumoniae can be help-
ful in de-escalating antimicrobial therapy, a mat-
ter of particular importance in this era of
antimicrobial resistance. Hopefully, a reduction
in antimicrobial use will lead to reduced pressure
for emergence of resistance, as well as a reduction
in adverse events. Knowledge of the causative
pathogen can also contribute to the rational
selection of antimicrobial agents when changing
from intravenous to oral therapy in the hospital
setting.
Finally, regarding the issue of combination
therapy for bacteraemic pneumococcal pneu-
monia, it is important to note that these studies
evaluated the effects of initial empirical therapy
before the results of blood cultures were known
and did not examine the effects of pathogen-
speciﬁc therapy after the results of blood
cultures were available [34]. The beneﬁt of
combination therapy was also most pronounced
in the more severely ill patients. Therefore, no
data suggest that discontinuation of combination
therapy, once results of cultures are known, is
unsafe in non-intensive-care-unit patients. Thus,
if an appropriate culture reveals the presence of
penicillin-susceptible S. pneumoniae, a pathogen-
speciﬁc, narrow-spectrum agent (e.g., penicillin
or amoxycillin) can be selected, with the afore-
mentioned potential beneﬁts with respect to the
selective pressure for resistance.
CONCLUSION
The rapid detection of S. pneumoniae provides a
unique opportunity for more targeted use of
narrow-spectrum antibiotics, thus creating the
possibility of more rational antibiotic use. Further
studies on the clinical utility of existing and
newer technologies should provide the evidence
required for the integration of rapid tests and
early pathogen-directed therapy into routine
clinical practice.
The rapid diagnosis of S. pneumoniae for CAP
will require a different approach to clinical
management than is presently followed in many
countries. Presently, the general standard of care
for CAP is empirical therapy, with little emphasis
on microbiological identiﬁcation. However, we
may be entering an era in which aetiological
diagnosis will become paramount [35]. This is
stated in reference to the identiﬁcation of patho-
gens other than S. pneumoniae (e.g., community-
onset methicillin-resistant Staphylococcus aureus
and H5N1 Inﬂuenza A virus), which are not
effectively treated by most recommended empi-
rical antimicrobial regimens.
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